WO2001039797A3 - Artificial chromosome constructs containing nucleic acid sequences capable of directing the formation of a recombinant rna-virus - Google Patents

Artificial chromosome constructs containing nucleic acid sequences capable of directing the formation of a recombinant rna-virus Download PDF

Info

Publication number
WO2001039797A3
WO2001039797A3 PCT/EP2000/012063 EP0012063W WO0139797A3 WO 2001039797 A3 WO2001039797 A3 WO 2001039797A3 EP 0012063 W EP0012063 W EP 0012063W WO 0139797 A3 WO0139797 A3 WO 0139797A3
Authority
WO
WIPO (PCT)
Prior art keywords
rna
virus
dna
artificial chromosome
grna
Prior art date
Application number
PCT/EP2000/012063
Other languages
French (fr)
Other versions
WO2001039797A2 (en
Inventor
Sanchez Luis Enjuanes
Original Assignee
Consejo Superior Investigacion
Sanchez Luis Enjuanes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8310818&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2001039797(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to AU30051/01A priority Critical patent/AU785081B2/en
Priority to BR0016145-4A priority patent/BR0016145A/en
Priority to DK00990628.0T priority patent/DK1234024T4/en
Priority to AT00990628T priority patent/ATE267246T1/en
Priority to HU0203305A priority patent/HU228205B1/en
Priority to SI200030394T priority patent/SI1234024T2/en
Priority to US10/148,669 priority patent/US7445928B2/en
Priority to NZ518990A priority patent/NZ518990A/en
Priority to ES00990628T priority patent/ES2218276T5/en
Priority to JP2001541529A priority patent/JP4637432B2/en
Priority to MXPA02005525A priority patent/MXPA02005525A/en
Application filed by Consejo Superior Investigacion, Sanchez Luis Enjuanes filed Critical Consejo Superior Investigacion
Priority to EP00990628A priority patent/EP1234024B2/en
Priority to DE60010921T priority patent/DE60010921T3/en
Priority to SK761-2002A priority patent/SK7612002A3/en
Priority to CA002393325A priority patent/CA2393325A1/en
Priority to PL356390A priority patent/PL206816B1/en
Priority to IL14985900A priority patent/IL149859A0/en
Publication of WO2001039797A2 publication Critical patent/WO2001039797A2/en
Publication of WO2001039797A3 publication Critical patent/WO2001039797A3/en
Priority to NO20022419A priority patent/NO331812B1/en
Priority to IL149859A priority patent/IL149859A/en
Priority to US10/238,786 priority patent/US7368557B2/en
Priority to AU2006203327A priority patent/AU2006203327B2/en
Priority to US12/285,213 priority patent/US20100167352A1/en
Priority to US12/938,771 priority patent/US20110142879A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A61K39/225—Porcine transmissible gastroenteritis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20041—Use of virus, viral particle or viral elements as a vector
    • C12N2770/20043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20061—Methods of inactivation or attenuation
    • C12N2770/20062—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/20—Pseudochromosomes, minichrosomosomes
    • C12N2800/204—Pseudochromosomes, minichrosomosomes of bacterial origin, e.g. BAC
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites

Abstract

The present invention relates to methods of preparing a DNA comprising steps, wherein (a) a DNA comprising a full length copy of the genomic RNA (gRNA) or an RNA virus; or (b) a DNA comprising one or several fragments of a gRNA of an RNA virus, which fragments code for an RNA dependent RNA polymerase and at least one structural or non-structural protein; or (c) a DNA having a homology of at least 60% to the sequences of (a) or (b); is cloned into a bacterial artificial chromosome (BAC). Additionally, DNAs are provided, which comprise sequences derived from the genomic RNA (gRNA) of a coronavirus which sequences have a homology of at least 60% to the natural sequence of the virus and code for an RNA dependent RNA polymerase and at least one structural or no-structural protein, wherein a fragment of said DNA is capable of being transcribed into RNA which RNA can be assembled to a virion. Further, the use of these nucleic acids for preparation of viral RNA or virions as well as pharmaceutical preparations comprising these DNAs, viral RNAs or virions is disclosed.
PCT/EP2000/012063 1999-12-03 2000-11-30 Artificial chromosome constructs containing nucleic acid sequences capable of directing the formation of a recombinant rna-virus WO2001039797A2 (en)

Priority Applications (23)

Application Number Priority Date Filing Date Title
EP00990628A EP1234024B2 (en) 1999-12-03 2000-11-30 Artificial chromosome constructs containing nucleic acid sequences capable of directing the formation of a recombinant rna-virus
DE60010921T DE60010921T3 (en) 1999-12-03 2000-11-30 ARTIFICIAL CHROMOSOMES CONTAINING GENETIC INFORMATION FOR THE FORMATION OF RECOMBINANT RNA VIRUS
BR0016145-4A BR0016145A (en) 1999-12-03 2000-11-30 Infectious clones
SK761-2002A SK7612002A3 (en) 1999-12-03 2000-11-30 Artificial chromosome constructs containing nucleic acid sequences capable of directing the formation of a recombinant rna-virus
HU0203305A HU228205B1 (en) 1999-12-03 2000-11-30 Infectious clones
SI200030394T SI1234024T2 (en) 1999-12-03 2000-11-30 Artificial chromosome constructs containing nucleic acid sequences capable of directing the formation of a recombinant rna-virus
US10/148,669 US7445928B2 (en) 1999-12-03 2000-11-30 Bacterial artificial chromosome construct encoding recombinant coronavirus
NZ518990A NZ518990A (en) 1999-12-03 2000-11-30 Use of bacterial artificial chromosomes (BACs) to prepare heterologous DNA expression vectors to formulate vaccines
ES00990628T ES2218276T5 (en) 1999-12-03 2000-11-30 CONSTRUCTION OF ARTIFICIAL CHROMOSOMES CONTAINING SEQUENCES OF NUCLEIC ACIDS CAPABLE OF DIRECTING THE FORMATION OF A RECOMBINING VIRUS OF RNA.
JP2001541529A JP4637432B2 (en) 1999-12-03 2000-11-30 Infectious clone
MXPA02005525A MXPA02005525A (en) 1999-12-03 2000-11-30 Artificial chromosome constructs containing nucleic acid sequences capable of directing the formation of a recombinant rna-virus.
AU30051/01A AU785081B2 (en) 1999-12-03 2000-11-30 Artificial chromosome constructs containing nucleic acid sequences capable of directing the formation of a recombinant RNA-virus
IL14985900A IL149859A0 (en) 1999-12-03 2000-11-30 Infectious clones
DK00990628.0T DK1234024T4 (en) 1999-12-03 2000-11-30 Artificial chromosome constructs containing nucleic acid sequences capable of directing the formation of a recombinant RNA virus
AT00990628T ATE267246T1 (en) 1999-12-03 2000-11-30 ARTIFICIAL CHROMOSOMES CONTAINING THE GENETIC INFORMATION FOR THE FORMATION OF RECOMBINANT RNA VIRUS
CA002393325A CA2393325A1 (en) 1999-12-03 2000-11-30 Infectious clones
PL356390A PL206816B1 (en) 1999-12-03 2000-11-30 Artificial chromosome constructs containing nucleic acid sequences capable of directing the formation of a recombinant rna-virus
NO20022419A NO331812B1 (en) 1999-12-03 2002-05-22 Procedure for Preparing DNA Derived from Coronavirus as well as Infectious Clones, Recombinant Viral Vector, and Vaccine
IL149859A IL149859A (en) 1999-12-03 2002-05-27 Infectious clones
US10/238,786 US7368557B2 (en) 1999-12-03 2002-09-11 Polynucleotides encoding porcine transmissible gastroenteritis virus
AU2006203327A AU2006203327B2 (en) 1999-12-03 2006-08-03 Infectious clones
US12/285,213 US20100167352A1 (en) 1999-12-03 2008-09-30 Infectious clones
US12/938,771 US20110142879A1 (en) 1999-12-03 2010-11-03 Infectious clones

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES9902673 1999-12-03
ES009902673A ES2170622B1 (en) 1999-12-03 1999-12-03 CLONES AND INFECTIVE VECTORS DERIVED FROM CORONAVIRUS AND ITS APPLICATIONS.

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US10148669 A-371-Of-International 2000-11-30
US10/238,786 Continuation US7368557B2 (en) 1999-12-03 2002-09-11 Polynucleotides encoding porcine transmissible gastroenteritis virus
US12/285,213 Continuation US20100167352A1 (en) 1999-12-03 2008-09-30 Infectious clones

Publications (2)

Publication Number Publication Date
WO2001039797A2 WO2001039797A2 (en) 2001-06-07
WO2001039797A3 true WO2001039797A3 (en) 2002-01-24

Family

ID=8310818

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/012063 WO2001039797A2 (en) 1999-12-03 2000-11-30 Artificial chromosome constructs containing nucleic acid sequences capable of directing the formation of a recombinant rna-virus

Country Status (27)

Country Link
US (4) US7445928B2 (en)
EP (2) EP1437400A3 (en)
JP (1) JP4637432B2 (en)
KR (1) KR100755814B1 (en)
CN (3) CN1616670A (en)
AR (1) AR027893A1 (en)
AT (1) ATE267246T1 (en)
AU (2) AU785081B2 (en)
BR (1) BR0016145A (en)
CA (1) CA2393325A1 (en)
CZ (1) CZ302785B6 (en)
DE (1) DE60010921T3 (en)
DK (1) DK1234024T4 (en)
ES (2) ES2170622B1 (en)
HU (1) HU228205B1 (en)
IL (2) IL149859A0 (en)
MX (1) MXPA02005525A (en)
NO (1) NO331812B1 (en)
NZ (1) NZ518990A (en)
PL (1) PL206816B1 (en)
PT (1) PT1234024E (en)
RS (1) RS50372B (en)
SI (1) SI1234024T2 (en)
SK (1) SK7612002A3 (en)
TR (1) TR200401186T4 (en)
WO (1) WO2001039797A2 (en)
ZA (1) ZA200203560B (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2170622B1 (en) 1999-12-03 2004-05-16 Consejo Superior De Investigaciones Cientificas CLONES AND INFECTIVE VECTORS DERIVED FROM CORONAVIRUS AND ITS APPLICATIONS.
US7556957B2 (en) 2001-05-17 2009-07-07 Stichting Voor De Technische Wetenschappen Coronavirus-like particles comprising functionally deleted genomes
HU228121B1 (en) * 2001-05-17 2012-11-28 Stichting Tech Wetenschapp Corona-virus-like particles comprising functionally deleted genomes
US7906311B2 (en) 2002-03-20 2011-03-15 Merial Limited Cotton rat lung cells for virus culture
US7371837B2 (en) * 2004-07-21 2008-05-13 The University Of Hong Kong Human virus causing respiratory tract infection and uses thereof
EP1619246A1 (en) * 2004-07-23 2006-01-25 Université de la Méditerranée, Aix-Marseille II RNA dependent RNA polymerases from coronavirus and their use in molecular biology and drug screening
EP1632247A1 (en) * 2004-09-03 2006-03-08 Consejo Superior De Investigaciones Cientificas Nucleic acid sequences encoding FMDV proteins capable of associating into a virus-like particle
US20060165723A1 (en) 2004-09-03 2006-07-27 Consejo Superior De Investigaciones Cientificas Nucleic acid sequences encoding proteins capable of associating into a virus-like particle
CA3079874C (en) 2004-10-22 2023-01-03 Revivicor, Inc. Ungulates with genetically modified immune systems
EP1792996A1 (en) * 2005-12-01 2007-06-06 Consejo Superior de Investigaciones Cientificas Nucleic acid sequences encoding vaccines against Porcine reproductive and respiratory syndrome virus (PRRSV)
JP2007312649A (en) * 2006-05-24 2007-12-06 Japan Health Science Foundation Reconstructed infectious retrovirus genome clone dna, microorganism containing the same dna and method for producing the same dna
EP2348827B1 (en) 2008-10-27 2015-07-01 Revivicor, Inc. Immunocompromised ungulates
FR2947839A1 (en) * 2009-07-09 2011-01-14 Centre Nat Rech Scient New isolated nucleic acid comprising a nucleotide sequence of a bacterial replicon centromere, useful for treating infection caused by Burkholderia and glanders and melioidosis
EP2681232A1 (en) 2011-03-02 2014-01-08 Intervet International B.V. Infectious bronchitis virus (ibv) spike protein as subunit vaccine
GB201307528D0 (en) * 2013-04-26 2013-06-12 Univ Leuven Kath Bacterial artificial chromosomes
US9987353B2 (en) * 2014-05-16 2018-06-05 Yale University Virus like vesicles (VLVS) based vaccines to prevent or treat chronic hepatitis B virus (HBV) infection
EP3143145A4 (en) * 2014-05-16 2017-12-27 Yale University Evolution of high-titer virus-like vesicles for vaccine applications
JP6875274B6 (en) 2014-09-22 2021-06-30 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ Reverse genetics system of pitindevirus and how to use
GB201603374D0 (en) 2016-02-26 2016-04-13 Ucl Business Plc Packaging cell
CN107190022B (en) * 2017-06-28 2020-10-30 浙江大学 Method for quickly constructing reverse genetic strain of avian infectious bronchitis virus
US11254953B2 (en) * 2018-04-18 2022-02-22 Utah State University Compositions and methods for zika virus characterization and vaccine development
KR102119875B1 (en) * 2019-03-19 2020-06-05 한국화학연구원 South Korean strain Middle East Respiratory syndrome coronavirus Infectious mutated gene and use thereof
CN110468113A (en) * 2019-08-07 2019-11-19 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） The transmissible gastro-enteritis virus velogen strain of recombinant modified and its application
CN110656120A (en) * 2019-10-16 2020-01-07 中国医学科学院医学生物学研究所 Cloning method and application of Japanese encephalitis virus SA14-14-2
CN111662885A (en) * 2020-06-22 2020-09-15 扬州大学 Construction, rescue and application of infectious clone of virulent and attenuated strains of two highly homologous genome porcine reproductive and respiratory syndrome viruses
CN112852873B (en) * 2021-02-04 2023-03-24 华中农业大学 Construction method of porcine delta coronavirus infectious clone plasmid

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995003400A1 (en) * 1993-07-23 1995-02-02 Johns Hopkins University School Of Medicine Recombinationally targeted cloning in yeast artificial chromosomes
WO1997034008A1 (en) * 1996-03-14 1997-09-18 Cyanamid Iberica, S.A. Vectors based on recombinant defective viral genomes, and their use in the formulation of vaccines
WO1999006582A1 (en) * 1997-08-01 1999-02-11 Koszinowski Ulrich H Recombinant vector containing infectious, viral genome sequences greater than 100 kb, method for producing same and use for the mutagenesis of the viral sequences
WO1999043842A1 (en) * 1998-02-26 1999-09-02 Neurovir, Inc. Artificial chromosome constructs containing nucleic acid sequences capable of directing the formation of a recombinant virus

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5833975A (en) * 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US5288641A (en) * 1984-06-04 1994-02-22 Arch Development Corporation Herpes Simplex virus as a vector
US5545412A (en) * 1985-01-07 1996-08-13 Syntex (U.S.A.) Inc. N-[1, (1-1)-dialkyloxy]-and N-[1, (1-1)-dialkenyloxy]-alk-1-yl-n,n,n-tetrasubstituted ammonium lipids and uses therefor
US4946787A (en) * 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5106733A (en) * 1987-06-25 1992-04-21 Immunex Corporation Bovine granulocyte-macrophage colony stimulating factor
JPH04503306A (en) 1989-02-01 1992-06-18 ザ・ジェネラル・ホスピタル・コーポレーション Herpes simplex virus type 1 expression vector
US5811103A (en) * 1989-03-19 1998-09-22 Akzo Nobel N.V. Hog cholera virus vaccine and diagnostic
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
CA2039921A1 (en) 1990-04-16 1991-10-17 Xandra O. Breakefield Transfer and expression of gene sequences into central nervous system cells using herpes simplex virus mutants with deletions in genes for viral replication
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
EP0575491B1 (en) * 1991-03-07 2003-08-13 Virogenetics Corporation Genetically engineered vaccine strain
ES2026827A6 (en) * 1991-03-26 1992-05-01 Ercros Sa Method for producing a subunit vaccine against porcine parvovirus.
US6033904A (en) * 1992-01-13 2000-03-07 Syntro Corporation Recombinant swinepox virus
US5382425A (en) * 1992-01-13 1995-01-17 Syntro Corporation Recombinant swinepox virus
US5658724A (en) * 1992-07-31 1997-08-19 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus strains deficient for the essential immediate early genes ICP4 and ICP27 and methods for their production, growth and use
KR100374295B1 (en) * 1993-02-08 2003-12-24 바이엘 코포레이션 Methods for growing pigs and respiratory syndrome virus and their use in vaccines
DE69434447T2 (en) * 1993-06-07 2006-05-18 Vical, Inc., San Diego PLASMIDE FOR GENE THERAPY
US20020146392A1 (en) 1993-06-24 2002-10-10 Frank L. Graham Helper dependent adenovirus vectors based on site-specific recombinases
US6015686A (en) * 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
CA2190121A1 (en) * 1994-03-15 1995-09-21 Edith Mathiowitz Polymeric gene delivery system
WO1995030018A2 (en) * 1994-04-29 1995-11-09 Immuno Aktiengesellschaft Recombinant poxviruses with foreign polynucleotides in essential regions
DK53595A (en) * 1994-05-13 1995-11-14 Iberica Cyanamid Recombinant PRRSV proteins, diagnostic kits and vaccines containing such recombinant PRRSV proteins
US5585096A (en) * 1994-06-23 1996-12-17 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
GB9415319D0 (en) 1994-07-29 1994-09-21 Medical Res Council HSV viral vector
AU4367096A (en) 1994-11-21 1996-06-17 Trustees Of Columbia University In The City Of New York, The Unique associated kaposi's sarcoma virus sequences and uses thereof
US5719131A (en) * 1994-12-09 1998-02-17 Genzyme Corporation Cationic amphiphiles containing dialkylamine lipophilic groups for intracellular delivery of therapeutic molecules
EP1683858A3 (en) 1995-02-21 2006-08-02 Cantab Pharmaceuticals Research Limited Viral preparations, vectors, immunogens, and vaccines
US6043232A (en) * 1997-07-23 2000-03-28 Nitromed, Inc. Nitroso esters of beta-oxo-amides and aryl propionic acid derivatives of non-steroidal antiinflammatory drugs
US6019980A (en) * 1995-06-07 2000-02-01 Connaught Laboratories Limited Nucleic acid respiratory syncytial virus vaccines
US5820869A (en) * 1995-06-07 1998-10-13 American Home Products Corporation Recombinant raccoon pox viruses and their use as an effective vaccine against feline immunodeficiency virus infection
US5705385A (en) * 1995-06-07 1998-01-06 Inex Pharmaceuticals Corporation Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US5851826A (en) 1995-07-26 1998-12-22 Children's Medical Center Corporation Helper virus-free herpesvirus vector packaging system
US5795872A (en) * 1995-09-19 1998-08-18 Pharmadigm, Inc. DNA construct for immunization
US6133243A (en) 1996-02-22 2000-10-17 Onyx Pharmaceuticals, Inc. Liposomal-viral DNA complexes for treating disease
FR2751224B1 (en) * 1996-07-19 1998-11-20 Rhone Merieux POLYNUCLEOTIDE VACCINE FORMULA AGAINST BREATHING AND PIG REPRODUCTIVE CONDITIONS
US5990091A (en) * 1997-03-12 1999-11-23 Virogenetics Corporation Vectors having enhanced expression, and methods of making and uses thereof
US6004777A (en) * 1997-03-12 1999-12-21 Virogenetics Corporation Vectors having enhanced expression, and methods of making and uses thereof
US7211379B2 (en) * 1997-10-03 2007-05-01 Merial Sas Prevention of myocarditis, abortion and intrauterine infection associated with porcine circovirus-2
US6517843B1 (en) * 1999-08-31 2003-02-11 Merial Reduction of porcine circovirus-2 viral load with inactivated PCV-2
FR2781159B1 (en) * 1998-07-06 2000-10-06 Merial Sas CIRCOVIRUS VACCINE AND PIG PARVOVIRUS
US6391314B1 (en) * 1997-10-03 2002-05-21 Merial Porcine circoviruses vaccines diagnostic reagents
UA78180C2 (en) * 1997-10-03 2007-03-15 Меріаль Porcine circovirus, vaccines and diagnostic reagents
US6165493A (en) * 1997-10-22 2000-12-26 New York Blood Center, Inc. "Methods and compositions for decreasing the frequency of HIV, herpesvirus and sexually transmitted bacterial infections"
FR2772047B1 (en) * 1997-12-05 2004-04-09 Ct Nat D Etudes Veterinaires E GENOMIC SEQUENCE AND POLYPEPTIDES OF CIRCOVIRUS ASSOCIATED WITH PIGLET LOSS DISEASE (MAP), APPLICATIONS TO DIAGNOSIS AND TO PREVENTION AND / OR TREATMENT OF INFECTION
US20040062775A1 (en) * 1997-12-05 2004-04-01 Agence Francaise De Securite Sanitaire Des Aliments Circovirus sequences associated with piglet weight loss disease (PWD)
PT2363488E (en) * 1997-12-11 2015-01-13 Univ Belfast Postweaning multisystemic wasting syndrome virus from pigs
WO1999045956A1 (en) * 1998-03-13 1999-09-16 University Of Georgia Research Foundation, Inc. Vaccines against circovirus infections
US6497883B1 (en) * 1999-06-10 2002-12-24 Merial Porcine circovirus recombinant poxvirus vaccine
ES2170622B1 (en) 1999-12-03 2004-05-16 Consejo Superior De Investigaciones Cientificas CLONES AND INFECTIVE VECTORS DERIVED FROM CORONAVIRUS AND ITS APPLICATIONS.
ES2281369T3 (en) 1999-12-14 2007-10-01 Novartis Ag VECTORS BASED ON THE VIRUS OF THE RECOMBINANT BOVINE IMMUNODEFICIENCY (BIV).
AU2001264802A1 (en) * 2000-05-21 2001-12-03 University Of North Carolina At Chapel Hill Assembly of large viral genomes and chromosomes from subclones
DE10044648A1 (en) * 2000-09-08 2002-03-21 Aventis Behring Gmbh Process for the propagation or removal of Cirocoviruses from biological material
EP1379671B1 (en) * 2001-03-27 2009-05-06 University of Saskatchewan Methods to culture circovirus

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995003400A1 (en) * 1993-07-23 1995-02-02 Johns Hopkins University School Of Medicine Recombinationally targeted cloning in yeast artificial chromosomes
WO1997034008A1 (en) * 1996-03-14 1997-09-18 Cyanamid Iberica, S.A. Vectors based on recombinant defective viral genomes, and their use in the formulation of vaccines
WO1999006582A1 (en) * 1997-08-01 1999-02-11 Koszinowski Ulrich H Recombinant vector containing infectious, viral genome sequences greater than 100 kb, method for producing same and use for the mutagenesis of the viral sequences
WO1999043842A1 (en) * 1998-02-26 1999-09-02 Neurovir, Inc. Artificial chromosome constructs containing nucleic acid sequences capable of directing the formation of a recombinant virus

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ALMAZAN FERNANDO ET AL: "Engineering the largest RNA virus genome as an infectious bacterial artificial chromosome.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 97, no. 10, 9 May 2000 (2000-05-09), May 9, 2000, pages 5516 - 5521, XP002166823, ISSN: 0027-8424 *
LAI, MICHAEL M. C.: "The making of infectious viral RNA: no size limit in sight", PROC. NATL. ACAD. SCI. U. S. A. (2000), 97(10), 5025-5027, 9 May 2000 (2000-05-09), XP002166822 *

Also Published As

Publication number Publication date
CA2393325A1 (en) 2001-06-07
CN1872994A (en) 2006-12-06
ES2218276T5 (en) 2010-10-07
HU228205B1 (en) 2013-01-28
AU3005101A (en) 2001-06-12
US20040086846A1 (en) 2004-05-06
SI1234024T2 (en) 2010-10-29
DK1234024T3 (en) 2004-09-13
AU2006203327A1 (en) 2006-08-31
KR20020060251A (en) 2002-07-16
WO2001039797A2 (en) 2001-06-07
IL149859A (en) 2009-07-20
ATE267246T1 (en) 2004-06-15
SI1234024T1 (en) 2004-08-31
CN100402643C (en) 2008-07-16
AR027893A1 (en) 2003-04-16
CN1616670A (en) 2005-05-18
JP4637432B2 (en) 2011-02-23
BR0016145A (en) 2002-08-13
AU785081B2 (en) 2006-09-14
PT1234024E (en) 2004-08-31
US20030148325A1 (en) 2003-08-07
RS50372B (en) 2009-11-10
HUP0203305A3 (en) 2004-07-28
EP1437400A3 (en) 2004-10-20
ZA200203560B (en) 2003-03-26
EP1437400A2 (en) 2004-07-14
EP1234024B2 (en) 2010-06-16
CZ20021882A3 (en) 2002-11-13
IL149859A0 (en) 2002-11-10
YU37502A (en) 2005-11-28
PL206816B1 (en) 2010-09-30
EP1234024B1 (en) 2004-05-19
ES2218276T3 (en) 2004-11-16
KR100755814B1 (en) 2007-09-07
NO20022419L (en) 2002-07-30
HUP0203305A2 (en) 2003-01-28
NO331812B1 (en) 2012-04-10
US7445928B2 (en) 2008-11-04
US7368557B2 (en) 2008-05-06
NZ518990A (en) 2004-03-26
JP2003515335A (en) 2003-05-07
TR200401186T4 (en) 2004-07-21
DE60010921D1 (en) 2004-06-24
DK1234024T4 (en) 2010-10-11
US20100167352A1 (en) 2010-07-01
CZ302785B6 (en) 2011-11-09
ES2170622B1 (en) 2004-05-16
NO20022419D0 (en) 2002-05-22
US20110142879A1 (en) 2011-06-16
SK7612002A3 (en) 2002-11-06
DE60010921T2 (en) 2006-05-11
CN1402780A (en) 2003-03-12
MXPA02005525A (en) 2004-09-10
AU2006203327B2 (en) 2009-09-10
DE60010921T3 (en) 2011-01-05
EP1234024A2 (en) 2002-08-28
ES2170622A1 (en) 2002-08-01
PL356390A1 (en) 2004-06-28

Similar Documents

Publication Publication Date Title
WO2001039797A3 (en) Artificial chromosome constructs containing nucleic acid sequences capable of directing the formation of a recombinant rna-virus
Andersson et al. A defined subgenomic fragment of in vitro synthesized Moloney sarcoma virus DNA can induce cell transformation upon transfection
US5091309A (en) Sindbis virus vectors
de Villiers et al. A small segment of polyoma virus DNA enhances the expression of a cloned β-globin gene over a distance of 1400 base pairs
Van Vliet et al. Discontinuous and non‐discontinuous subgenomic RNA transcription in a nidovirus
Cornelissen et al. Complete nucleotide sequence of tobacco streak virus RNA 3
Carter et al. Identification and sequence determination of the capsid protein gene of feline calicivirus
Shih et al. The choice of alternative 5'splice sites in influenza virus M1 mRNA is regulated by the viral polymerase complex.
WO2000003030A3 (en) Recombinant raccoonpox virus and uses thereof as a vaccine in mammalian and avian species
Shatkin et al. Reovirus mRNA: transcription and translation
Singh et al. Turnip Yellow Mosaic Virus RNA-Dependent RNA Polymerase: Initiation of Minus Strand Synthesisin Vitro
CA2196555A1 (en) Vr-2332 viral nucleotide sequence and methods of use
MY117686A (en) Infectious clones of rna viruses and vaccines and diagnostic assays derived thereof
DK605987D0 (en) Certain DNA sequences derived from a papilloma virus genome, their use for in vitro diagnostic and preparation of antigenic preparations
Cash et al. Genome complexities of the three mRNA species of snowshoe hare bunyavirus and in vitro translation of S mRNA to viral N polypeptide
Herman Alternatives for the initiation of translation
JP2004501646A5 (en)
Yang et al. Involvement of a subgenomic mRNA in the generation of a variable population of defective citrus tristeza virus molecules
Stupina et al. Analysisin Vivoof Turnip Crinkle Virus Satellite RNA C Variants with Mutations in the 3′-Terminal Minus-Strand Promoter
Osorio-Keese et al. Nucleotide sequence of the genome of eggplant mosaic tymovirus
Aloni et al. Attenuation May Regulate Gene Expression in Animal Viruses and Cell
Zaitlin Elucidation of the genome organization of tobacco mosaic virus
Smits et al. Torovirus non-discontinuous transcription: mutational analysis of a subgenomic mRNA promoter
US20080267992A1 (en) Sars Virus Vaccine with Adenovirus Carrier and Preparation Method Thereof, and Use of Sars Virus S Gene for Preparation of Vaccine
JP2011135897A (en) Modified nodavirus rna for gene delivery

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: P-375/02

Country of ref document: YU

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2002/00579/MU

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 518990

Country of ref document: NZ

Ref document number: 30051/01

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 149859

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 7612002

Country of ref document: SK

Ref document number: PV2002-1882

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 2393325

Country of ref document: CA

Ref document number: 008165904

Country of ref document: CN

Ref document number: 1200200477

Country of ref document: VN

ENP Entry into the national phase

Ref document number: 2001 541529

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/005525

Country of ref document: MX

Ref document number: 2000990628

Country of ref document: EP

Ref document number: 10148669

Country of ref document: US

Ref document number: 1020027007118

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 1020027007118

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2000990628

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV2002-1882

Country of ref document: CZ

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 518990

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 2000990628

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 518990

Country of ref document: NZ